Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "certificate of analysis"

Looking for quality documents?
event icon
Scaling Up? No Problem with New 80cm Diameter Pre-packed OPUS® Columns
Learn about OPUS® 80R Pre-packed Columns, the first and only pre-packed columns enabling the purification of over 10 kilos of protein in a single cycle. April 18, 2018 | 18 minutes
external link icon
Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer
event icon
Tulip tank case study: The unrecognized role of mixing during TFF
The degree of homogeneity in the feed that is delivered to the filters is a critical but often overlooked factor. Even small changes in the nature of the feed will drastically impact performance, resulting in deviations during diafiltration. This case study explores the impact of mixing dynamics on TFF performance. An innovative single-use Tulip Tank paired with the KrosFlo® RS 30 TFF system significantly improved performance as compared to traditional retentate vessels, reducing the gap between theoretical models and actual outcome.  
external link icon
Repligen Completes Expansion of U.S. Facility
WALTHAM, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System ("the ATF System"), the most recent addition to the Company's upstream bioprocessing product portfolio. The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment that meets the high standards of Repligen's biopharmaceutical customers. "This expansion satisfies our goal to rapidly transfer ATF System operations, which we acquired from Refine Technology of
external link icon
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
event icon
5th Annual Summit of Biologics Conferences and Workshop on Biopharmaceutical Product Development
Booth S2 - Novotel Dona Sylvia Resort, Goa, India
external link icon
Repligen Acquires Bioprocessing Business of Refine Technology
- Expands Portfolio of Products to Improve Efficiencies in Biologic Drug Manufacturing - - Company Updates 2014 Financial Guidance - - Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., June 3, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has acquired the business of Refine Technology ("Refine"), including Refine's Alternating Tangential Flow ("ATF") System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process. The acquisition strengthens Repligen's bioprocessing business by adding a profitable and highly complementary product line while expanding the Company's direct sales presence worldwide. Repligen has entered into a definitive agreement effective June 2, 2014 to purchase Refine's business for a combination of $20.5 million in cash and 215,285 shares of Repligen common stock, for total upfront consideration of approximately $24.5 million.
external link icon
Repligen Completes Expansion of U.S. Manufacturing Facility
WALTHAM, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met. A dedicated production suite more than doubles capacity for the Company's OPUS ® line of pre-packed chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment to satisfy the Good Manufacturing Practices (GMP) standards of the Company's biopharmaceutical customers. "This expansion will enable us to meet the critical needs of our customers for quality and timely delivery," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. "The new cleanroom suite enables us to produce OPUS ® columns under the highest quality standard demanded by
external link icon
Repligen Announces Support of Amended Stockholder Proposal
external link icon
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), today announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies and Fc-fusion proteins. Named NGL-Impact ® A Hi pH , the new ligand is the first to address antibody aggregation in low pH elution buffers. While developed specifically to address pH sensitive antibodies and Fc-fusion proteins, NGL-Impact A Hi pH ligand demonstrates high performance for all antibodies, and can be considered for “platform” use due to its broad pH operating range.
Ralf Kuriyel, Repligen Senior Vice President R&D, said, “This new best-in-class ligand addresses one of the major pain points in antibody drug purification which is the formation of aggregates during Protein A elution. Our new